Such multi-faceted activity of silibinin against STAT3, when used orally as part of the bioavailable Eurosil-85®/Euromed nutraceutical formulation contained in the nutraceutical product Legasil® [48], has proven therapeutically effective in patients with advanced NSCLC and was particularly notable in the central nervous system, where it provided greater than 4-fold survival benefit in patients with established brain metastases [49,50]. Here, STAT3 is linked to non-small cell lung carcinoma.